As the prevalence of obesity and type 2 diabetes is increasing in both men and women, and both men and women are receiving GLP-1RAs, further studies are required to determine the direct effects (if any) of GLP-1 and GLP-1RAs on reproductive hormone secretion in women and hypogonadal patients with obesity/diabetes. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.